January 11-14, 2027 | San Francisco Marriott Marquis
January 15, 2027 | Virtual
January 11-14, 2027 | San Francisco
January 15, 2027 | Virtual
January 11-14, 2027 | San Francisco Marriott Marquis
January 15, 2027 | Virtual
2027 Participating Companies
Kringle Pharma, Inc.
A late clinical-stage biopharmaceutical company focused on developing recombinant human HGF, KP-100, for the treatment of acute spinal cord injury, vocal fold scar and ALS.